Effect of research impact on emerging camel husbandry, welfare and social-related awareness

The lack of applied scientific research on camels, despite them being recognized as production animals, compels the reorganization of emerging camel breeding systems with the aim of achieving successful camel welfare management strategies all over the world. Relevant and properly-framed research widely impacts dissemination of scientific contents and drives public willingness to enhance ethically acceptable conditions for domestic animals. Consumer perception of this livestock industry will improve and high-quality products will be obtained. This paper draws on bibliometric indicators as promoting factors for camel-related research advances, tracing historical scientific publications indexed in ScienceDirect directory from 1880–2019. Camel as a species did not affect Journal Citation Reports (JCR) impact (p > 0.05) despite the journal, author number, corresponding author origin, discipline and publication year affecting it (p < 0.001). Countries with traditionally well-established camel farming are also responsible for the papers with the highest academic impact. However, camel research advances may have only locally and partially influenced welfare related laws, so intentional harming acts and basic needs neglect may persist in these species. A sustainable camel industry requires those involved in camel research to influence business stakeholders and animal welfare advocacies by highlighting the benefits of camel wellbeing promotion, co-innovation partnership establishment and urgent enhancement of policy reform

Camel genetic resources conservation through tourism: A key sociocultural approach of camelback leisure riding

Camels are exotic elements, which can be comprised within adventure travel companies promoting ecotourism activities. Such recreations contribute to sustainable livelihoods for local communities and educational empowerment towards nature and its conservation. At present, some local camel breeds’ survival reduces to this animal-based leisure industry and its reliability to perform and promote customized services accurately. By conducting an on-site questionnaire to customers participating in camelback riding tours, we assessed the motivational factors affecting participation, satisfaction, and loyalty in this tourism segment that may have made it socially differentiated. The sixfold combination of staff performance, culture geography, diverse and humane close interaction, camel behavior and performance, sociotemporal context, and positive previous experience involves the elemental dimensions that explain customer satisfaction and return intention probability within this entertainment business. Customer knowledge is essential for stakeholders to build personalized riding experiences and align profits with environmental sustainability and biodiversity mainstream concerns into their everyday operations. In turn, domestic camel tourist rides could be managed as a viable path to nature conservation by helping endangered local breeds to avoid their functional devaluation and potential extinction

Bayesian analysis of the association between casein complex haplotype variants and milk yield, composition, and curve shape parameters in murciano-granadina goats

Considering casein haplotype variants rather than SNPs may maximize the understanding of heritable mechanisms and their implication on the expression of functional traits related to milk production. Effects of casein complex haplotypes on milk yield, milk composition, and curve shape parameters were used using a Bayesian inference for ANOVA. We identified 48 single nucleotide polymorphisms (SNPs) present in the casein complex of 159 unrelated individuals of diverse ancestry, which were organized into 86 haplotypes. The Ali and Schaeffer model was chosen as the best fitting model for milk yield (Kg), protein, fat, dry matter, and lactose (%), while parabolic yield-density was chosen as the best fitting model for somatic cells count (SCC × 103 sc/mL). Peak and persistence for all traits were computed respectively. Statistically significant differences (p < 0.05) were found for milk yield and components. However, no significant difference was found for any curve shape parameter except for protein percentage peak. Those haplotypes for which higher milk yields were reported were the ones that had higher percentages for protein, fat, dry matter, and lactose, while the opposite trend was described by somatic cells counts. Conclusively, casein complex haplotypes can be considered in selection strategies for economically important traits in dairy goats

Software-automatized individual lactation model fitting, peak and persistence and Bayesian criteria comparison for milk yield genetic studies in Murciano-Granadina goats

SPSS model syntax was defined and used to evaluate the individual performance of 49 linear and non-linear models to fit the lactation curve of 159 Murciano-Granadina goats selected for genotyping analyses. Lactation curve shape, peak and persistence were evaluated for each model using 3107 milk yield controls with an average of 3.78 ± 2.05 lactations per goat. Best fit (Adjusted R2) values (0.47) were reached by the five-parameter logarithmic model of Ali and Schaeffer. Three main possibilities were detected: non-fitting (did not converge), standard (Adjusted R2 over 75%) and atypical curves (Adjusted R2 below 75%). All the goats fitted for 38 models. The ability to fit different possible functional forms for each goat, which progressively increased with the number of parameters comprised in each model, translated into a higher sensitivity to explaining curve shape individual variability. However, for models for which all goats fitted, only moderate increases in explanatory and predictive potential (AIC, AICc or BIC) were found. The Ali and Schaeffer model reported the best fitting results to study the genetic variability behind goat milk yield and perhaps enhance the evaluation of curve parameters as trustable future selection criteria to face the future challenges offered by the goat dairy industry

Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy

Cancer continues to be one of the major health and socio-economic problems worldwide, despite considerable efforts to improve its early diagnosis and treatment. The identification of new constituents as biomarkers for early diagnosis of neoplastic cells and the discovery of new type of drugs with their mechanistic actions are crucial to improve cancer therapy. New drugs have entered the market, thanks to industrial and legislative efforts ensuring continuity of pharmaceutical development. New targets have been identified, but cancer therapy and the anti-cancer drug market still partly depend on anti-mitotic agents. The objective of this paper is to show the effects of KAR-2, a potent anti-mitotic compound, and TPPP/p25, a new unstructured protein, on the structural and functional characteristics of the microtubule system. Understanding the actions of these two potential effectors on the microtubule system could be the clue for early diagnosis and improvement of cancer therapy

Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing (biowaiver) for the approval of immediate release (IR) solid oral dosage forms containing aciclovir are reviewed. Aciclovir therapeutic use and therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA) studies were also taken into consideration in order to ascertain whether a biowaiver can be recommended. According to the Biopharmaceutics Classification System (BCS) and considering tablet strengths up to 400 mg, aciclovir would be BCS Class III. However, in some countries also 800 mg tablets are available which fall just within BCS Class IV. Aciclovir seems not to be critical with respect to a risk for bio in equivalence, as no examples of bio in equivalence have been identified. It has a wide therapeutic index and is not used for critical indications. Hence, if: (a) the test product contains only excipients present in aciclovir solid oral IR drug products approved in ICH or associated countries, for instance as presented in this article; and (b) the comparator and the test product both are very rapidly dissolving , a biowaiver for IR aciclovir solid oral drug products is considered justified for all tablet strengths. © 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 97:5061–5073, 2008Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/61316/1/21392_ftp.pd

Heart failure with recovered ejection fraction: Clinical characteristics, determinants and prognosis. CARDIOCHUS-CHOP registry

Background: The magnitude and the prognostic impact of recovering left ventricular ejection fraction (LVEF) in patients with heart failure (HF) and systolic dysfunction is unclear. The aim of this study was to evaluate the clinical characteristics and prognosis of patients with HFrecEF in an HF population. Methods: 449 consecutive patients were selected with the diagnosis of HF and an evaluation of LVEF in the 6 months prior to selection who were referred to two HF units. Patients with systolic dysfunction were only considered if a second echocardiogram was performed during the follow-up. Results: At the time of diagnosis, 207 patients had LVEF > 40% (HFpEF) and 242 had LVEF ≤ 40% (HFrEF). After 1 year, the LVEF was re-evaluated in all 242 patients with a LVEF ≤ 40%: in 126 (52%), the second LVEF was > 40% (HFrecEF), and the remaining 116 (48%) had LVEF ≤ 40% (HFrEF). After 1800 ± 900 days of follow-up patients with recovered LVEF had a significantly lower mortality rate (HFpEF vs. HFrecEF: hazard ratio [HR] = 2.286, 95% confidence interval [95% CI] 1.264–4.145, p = 0.019; HFrEF vs. HFrecEF: HR = 2.222, 95% CI 1.189–4.186, p < 0.001) and hospitalization rate (HFpEF vs. HFrecEF: HR = 1.411, 95% CI 1.046–1.903, p = 0.024; HFrEF vs. HFrecEF: HR = 1.388, 95% CI 1.002–1.924, p = 0.049). The following are predictors of LVEF recovery: younger age, lower functional class, treatment with renin–angiotensin–aldosterone system inhibitors and beta-blockers, absence of defibrillator use, and non-ischemic etiology. Conclusions: Patients with HF and reduced LVEF who were re-evaluated after 1 year, had significant improvement in their LVEF and had a more favourable prognosis than HF with preserved and reduced ejection fraction